CN102178677B - 硝苯地平双层渗透泵药物组合物及其制备工艺 - Google Patents
硝苯地平双层渗透泵药物组合物及其制备工艺 Download PDFInfo
- Publication number
- CN102178677B CN102178677B CN201110049292.4A CN201110049292A CN102178677B CN 102178677 B CN102178677 B CN 102178677B CN 201110049292 A CN201110049292 A CN 201110049292A CN 102178677 B CN102178677 B CN 102178677B
- Authority
- CN
- China
- Prior art keywords
- layer
- double
- nifedipine
- osmotic pump
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 229960001597 nifedipine Drugs 0.000 title claims abstract description 21
- 230000003204 osmotic effect Effects 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title abstract description 24
- 239000000203 mixture Substances 0.000 title abstract description 10
- 238000005516 engineering process Methods 0.000 title abstract description 4
- 239000011248 coating agent Substances 0.000 claims abstract description 22
- 238000000576 coating method Methods 0.000 claims abstract description 22
- 238000013270 controlled release Methods 0.000 claims abstract description 17
- 239000012528 membrane Substances 0.000 claims abstract description 5
- -1 polyoxyethylene Polymers 0.000 claims description 20
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 19
- 230000001476 alcoholic effect Effects 0.000 claims description 18
- 239000007779 soft material Substances 0.000 claims description 18
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- 229920002301 cellulose acetate Polymers 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 229960003943 hypromellose Drugs 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 2
- 230000004584 weight gain Effects 0.000 claims description 2
- 235000019786 weight gain Nutrition 0.000 claims description 2
- 238000012946 outsourcing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 15
- 239000000463 material Substances 0.000 abstract description 7
- 229920002521 macromolecule Polymers 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 6
- 239000013543 active substance Substances 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 239000003086 colorant Substances 0.000 abstract description 4
- 239000004014 plasticizer Substances 0.000 abstract description 4
- 230000008961 swelling Effects 0.000 abstract description 4
- 239000000314 lubricant Substances 0.000 abstract description 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 3
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract description 2
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 239000003961 penetration enhancing agent Substances 0.000 abstract 1
- 239000008187 granular material Substances 0.000 description 24
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 238000000034 method Methods 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 206010020772 Hypertension Diseases 0.000 description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 7
- 239000004141 Sodium laurylsulphate Substances 0.000 description 6
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 235000012239 silicon dioxide Nutrition 0.000 description 5
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 238000005553 drilling Methods 0.000 description 4
- 239000007888 film coating Substances 0.000 description 4
- 238000009501 film coating Methods 0.000 description 4
- 238000003475 lamination Methods 0.000 description 4
- 230000005070 ripening Effects 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003405 delayed action preparation Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 239000003361 porogen Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940127088 antihypertensive drug Drugs 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 201000001068 Prinzmetal angina Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000000219 Sympatholytic Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 208000009325 Variant Angina Pectoris Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000000948 sympatholitic effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110049292.4A CN102178677B (zh) | 2011-03-02 | 2011-03-02 | 硝苯地平双层渗透泵药物组合物及其制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110049292.4A CN102178677B (zh) | 2011-03-02 | 2011-03-02 | 硝苯地平双层渗透泵药物组合物及其制备工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102178677A CN102178677A (zh) | 2011-09-14 |
CN102178677B true CN102178677B (zh) | 2015-01-21 |
Family
ID=44565084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110049292.4A Active CN102178677B (zh) | 2011-03-02 | 2011-03-02 | 硝苯地平双层渗透泵药物组合物及其制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102178677B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108403653A (zh) * | 2018-03-16 | 2018-08-17 | 中国药科大学 | 一种硝苯地平控释包芯片及其制备方法 |
CN111228235A (zh) * | 2020-03-06 | 2020-06-05 | 德州博诚制药有限公司 | 一种硝苯地平控释片及其制备方法 |
CN113425847A (zh) * | 2020-03-23 | 2021-09-24 | 上海汉都医药科技有限公司 | 片剂包衣膜及其原料组合物和制备、控释片剂及其制备 |
CN114053237A (zh) * | 2020-07-30 | 2022-02-18 | 上海汉都医药科技有限公司 | 一种控释片剂及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1628640A (zh) * | 2003-12-15 | 2005-06-22 | 哈尔滨市神龙中药药物研究所 | 择时释放渗透泵控释片 |
CN1931167A (zh) * | 2006-06-28 | 2007-03-21 | 广州贝氏药业有限公司 | 非洛地平双层渗透泵控释药物组合物 |
-
2011
- 2011-03-02 CN CN201110049292.4A patent/CN102178677B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1628640A (zh) * | 2003-12-15 | 2005-06-22 | 哈尔滨市神龙中药药物研究所 | 择时释放渗透泵控释片 |
CN1931167A (zh) * | 2006-06-28 | 2007-03-21 | 广州贝氏药业有限公司 | 非洛地平双层渗透泵控释药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN102178677A (zh) | 2011-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005324132B2 (en) | Solid, orally applicable pharmaceutical administration forms containing rivaroxaban having modified release | |
CN102917697B (zh) | 用于高剂量的水溶性和吸湿性药物的控释剂型 | |
KR100831771B1 (ko) | 서방출과 pH 의존성 속방출을 나타내는 약제학적 조성물 | |
EP2961383B1 (en) | Suspension for oral administration comprising amorphous tolvaptan | |
JP2011513204A (ja) | 口腔内崩壊性固形製剤 | |
EP2740471B1 (en) | Oral pharmaceutical composition comprising dabigatran etexilate | |
CN102178677B (zh) | 硝苯地平双层渗透泵药物组合物及其制备工艺 | |
TW200810793A (en) | Asymmetric membranes for drug delivery devices | |
TW201414508A (zh) | 含5-氯-n-({(5s)-2-側氧-3-[4-(3-側氧-4-嗎啉基)苯基]-1,3-□唑啶-5-基}甲基)-2-噻吩甲醯胺之醫藥投遞型式 | |
CN110368371A (zh) | 一种新型控释片 | |
CN104146978A (zh) | 一种双硫仑肠溶片剂及其制备方法 | |
WO2005115346A2 (en) | Pharmaceutical composition containing risperidone | |
CN102349880B (zh) | 伊拉地平控释片及其制备方法 | |
WO2009027786A2 (en) | Matrix dosage forms of varenicline | |
CN110251473A (zh) | 羟哌吡酮口服缓释制剂 | |
US20230364075A1 (en) | Multiparticulate dosage forms comprising deutetrabenazine | |
EP3331502B1 (en) | Controlled release propiverine formulations | |
JP2020518611A (ja) | 水溶解度及びバイオアベイラビリティが改善された組成物 | |
CN114432254A (zh) | 一种硝苯地平控释片 | |
CN102144985B (zh) | 一种氯化钾单室渗透泵控释片及其制备方法 | |
CN108096251B (zh) | 一种吉非替尼药物组合物及其制备方法 | |
CN103599086B (zh) | 银杏叶总黄酮双层渗透泵控释片及制备方法 | |
JP5919173B2 (ja) | 徐放性塩酸アンブロキソール口腔内崩壊錠 | |
CN108186696B (zh) | 一种银杏内酯双层控释片及其制备方法 | |
CN102302469B (zh) | 非洛地平双层渗透泵控释片的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Science and Technology Industrial Park D-5 No. 168 high tech Zone camphor road in Hefei city of Anhui Province in 230088 Applicant after: HEFEI HUAFANG PHARMACEUTICAL SCIENCES & TECHNOLOGY Co.,Ltd. Address before: Tianda high tech Zone 230088 Hefei Road, Anhui province No. 71 Huayi Science Park G block four building Applicant before: HEFEI HUAFANG PHARMACEUTICAL SCIENCES & TECHNOLOGY Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Nifedipine bilayer osmotic pump drug composition and its preparation process Effective date of registration: 20231228 Granted publication date: 20150121 Pledgee: China Construction Bank Corporation Hefei Shushan sub branch Pledgor: HEFEI HUAFANG PHARMACEUTICAL SCIENCES & TECHNOLOGY Co.,Ltd. Registration number: Y2023980075424 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |